CG Oncology Shares Rise Following Positive Phase 3 Trial Results for Bladder Cancer Immunotherapy

CG Oncology (CGON) shares increased approximately 9% during Monday morning trading following the announcement of successful phase 3 data. The PIVOT-006 trial evaluated cretostimogene grenadenorepvec, an adjuvant intravesical immunotherapy designed for patients with non-muscle invasive bladder cancer (NMIBC). The clinical trial met its primary endpoint, demonstrating a statistically significant reduction in the risk of recurrence compared to the control group. This development marks a potential milestone for the company's pipeline and its approach to treating NMIBC.

By https://seekingalpha.com/user/53161691/bio · Seeking Alpha ·

CG Oncology Shares Rise Following Positive Phase 3 Trial Results for Bladder Cancer Immunotherapy

Tickers: $CGON

Topics: Immunotherapy NMIBC Phase 3 clinical trial Stock price movement

Read the full article at Seeking Alpha

Part of the story Biotech Sector Experiences Mixed Clinical and Regulatory Results (3 articles)

More World news